Emerging research suggest this peptide, a dual agonist targeting both GLP-1 and another hormone, could represent a significant advancement for weight management . Early patient trials have demonstrated https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide